A study of TQB2825 for CD20-positive blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called TQB2825, given as a shot under the skin, for people with certain types of blood cancer (B-cell lymphomas) that have come back or stopped responding to previous CD20 antibody treatments. The goal is to see if it is safe and works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have a type of B-cell lymphoma (like diffuse large B-cell, follicular, mantle cell, or marginal zone) that is CD20-positive.
- You have already tried at least one treatment that included a CD20 antibody (like rituximab) and it didn't work well enough or your cancer came back.
- You have at least one tumor that can be measured on a CT scan (lymph node at least 1.5 cm wide, or a tumor outside a lymph node at least 1 cm wide).
- Your blood counts and organ function (liver, kidneys, blood clotting) are good enough without needing transfusions or growth factors recently.
- You are not pregnant and agree to use birth control during the study and for 12 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQB2825 against standard immunotherapy for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if TQB2825 works better at controlling the lymphoma.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
This trial tests an experimental oral capsule called TQB3019 for people with advanced blood cancers that have come back or not improved with other treatments. The goal is to see if the drug is safe and to find the right dose.
This study tests a new injection called TQB2930 designed to treat advanced solid cancers (cancers that have spread) that have HER2 protein on their surface. The goal is to see if this treatment can shrink these tumors and help patients live longer.
This trial tests a new drug called TQB6411 for people with lung cancer. It aims to see if the drug is safe and effective, and what side effects it might have.
Hear when a new CD20-positive Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.